THE ROLE OF SURVIVIN AND RAF-1 KINASE AGAINST ENHANCEMENT OF PANCREATIC BETA-CELL APOPTOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

  • Eva Decroli Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Dr. M. Djamil General Hospital/Medical Faculty, Andalas University, Padang, Indonesia.
  • Asman Manaf Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Dr. M. Djamil General Hospital/Medical Faculty, Andalas University, Padang, Indonesia.
  • Syafril Syahbuddin Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Dr. M. Djamil General Hospital/Medical Faculty, Andalas University, Padang, Indonesia.
  • Sarwono Waspadji Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Medical Faculty, Indonesia University, Jakarta, Indonesia.
  • Dwisari Dillasamola Department of Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

Abstract

Objective: This study aimed to reveal differences in levels of survivin and Raf-1 kinase in prediabetes, controlled Type 2 diabetes mellitus (T2DM), uncontrolled T2DM, and their relationship with hemoglobin A1c (HbA1c) levels and serum triglyceride levels.

Methods: This study was an observational study with a cross-sectional design. The study involved 60 people with T2DM who visited the endocrine and metabolic clinic and 30 prediabetes patients. The variables were survivin levels and Raf-1 kinase enzymes that examined using enzyme-linked immunosorbent assay techniques. HbA1c values are measured by high-performance liquid chromatography and triglyceride levels measured by enzymatic method.

Results: Average levels of Raf-1 kinase were significantly higher in the prediabetes group, controlled T2DM, and uncontrolled T2DM (11.6±1.4 pg mL, 9.9±1.1 pg/mL, and 9.1±1.5 pg/mL). Survivin was significantly higher in the prediabetes group, controlled T2DM, and uncontrolled T2DM (5.4±0.4 pg mL, 5.0±0.2 pg/mL, and 4.7±0.1 pg/mL). There was no correlation between HbA1c with Raf-1 kinase levels (R=−0.215, p=0.250), but there was a correlation between HbA1c with serum survivin levels (R=−0.6, *p<0.05). There was a correlation between the levels of triglycerides with survivin but not with Raf-1 kinase (R=−0.267, *p=0.039).

Conclusion: Survivin and Raf-1 kinase levels are lower in uncontrolled T2DM. This explained the role of survivin and Raf-1 kinase against enhancement of pancreatic beta-cell apoptosis in patients with T2DM.

Keywords: Survivin, Raf-1 kinase, Hemoglobin A1c, Type 2 diabetes mellitus.

References

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Pathogenesis and treatment. Lancet 2008;371:2153-6.
3. Dussa KN, Sahay RK, Ndararajan PM, Hanarao MV. Adaptation of diabetes knowledge questionnaire for South Asian countries context. Int J Pharm Pharm Sci 2017;9:252-6.
4. Hussain M, Naqvi SB, Khan MA, Rizvi M, Alam S, Abbas A, et al. Direct cost of treatment of diabetes mellitus Type 2 in Pakistan. Int J Pharm Pharm Sci 2014;6:261-4.
5. Presetiawati I, Andrajati R, Sauriasari R. Effectiveness of a medication booklet and counseling on treatment adherence in Type 2 diabetes mellitus patients. Int J App Pharm 2017;9:27-31.
6. Dharma S, Macson J, Tobat SR, Dillasamola D. Effect of giving white egg chicken embryo and green beans (Phaseolus radiates) to the histopathology of pancreatic beta-cell from diabetic rats (Rattus novergicus). Res J Pharm Biol Chem Sci 2016;7:2059-67.
7. Roskoski R Jr. RAF protein-serine/threonine kinases: Structure and regulation. Biochem Biophys Res Commun 2010;399:313-7.
8. Chiou SK, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: Its biological roles and implications for cancer and beyond. Med Sci Monit 2003;9:PI25-9.
9. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to Type 2 diabetes in obese youth: Pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 2010;33:2225-31.
10. Wang H, Gambosova K, Cooper ZA, Holloway MP, Kassai A, Izquierdo D, et al. EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells. BMC Mol Biol 2010;11:66.
11. Bonora E. Protection of pancreatic beta-cells: Is it feasible? Nutr Metab Cardivasc Dis 2008;18:74-83.
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with Type 2 diabetes. Diabetes 2003;52:102-10.
13. Marchetti P, Del Prato S, Lupi R, Del Guerra S. The pancreatic beta-cell in human Type 2 diabetes. Nutr Metab Cardiovasc Dis 2006;16 Suppl 1:S3-6.
14. Wu X, Zhang Q, Wang X, Zhu J, Xu K, Okada H, et al. Survivin is required for beta-cell mass expansion in the pancreatic duct-ligated mouse model. PLoS One 2012;7:e41976.
15. Beith JL, Alejandro EU, Johnson JD. Insulin stimulates primary beta-cell proliferation via Raf-1 kinase. Endocrinology 2008;149:2251-60.
16. Ju L, Zhang X, Deng Y, Han J, Yang J, Chen S, et al. Enhanced expression of survivin has distinct roles in adipocyte homeostasis. Cell Death Dis 2017;8:e2533.
17. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of Type 2 diabetes. Endocr Rev 2002;23:599-622.
18. Lingohr MK, Buettner R, Rhodes CJ. Pancreatic beta-cell growth and survival – a role in obesity-linked Type 2 diabetes? Trends Mol Med 2002;8:375-84.
Statistics
104 Views | 179 Downloads
Citatons
How to Cite
Decroli, E., A. Manaf, S. Syahbuddin, S. Waspadji, and D. Dillasamola. “THE ROLE OF SURVIVIN AND RAF-1 KINASE AGAINST ENHANCEMENT OF PANCREATIC BETA-CELL APOPTOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 11, Nov. 2018, pp. 344-7, doi:10.22159/ajpcr.2018.v11i11.27671.
Section
Original Article(s)